Canonical: https://ownershiptrace.com/13f/companies/3543

# Who owns BioXcel Therapeutics, Inc. (BTAI)? Elite investor 13F holders

1 tracked elite investors reported holding BioXcel Therapeutics, Inc as of 2026-06-30, including Oaktree Capital Management. Who bought, trimmed or exited each quarter, with links to the original SEC 13F filings.

1 tracked investors currently reported holding · Latest report period: 2026-06-30 · Health Care · Pharmaceuticals, Biotechnology & Life Sciences

BioXcel Therapeutics, Inc., together with its subsidiary, OnkosXcel Therapeutics LLC, operates as a biopharmaceutical company that utilizes artificial intelligence approaches to develop medicines in neuroscience and immuno-oncology in the United States. The company IGALMI, a sublingual film for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.…

## Reported holders and securities, including exits (up to 20)

| Investor | Security | Instrument | Report period | Filed | Value | Quantity | Units | Change | Source |
|  --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| [Oaktree Capital Management](https://ownershiptrace.com/13f/investors/44) | BIOXCEL THERAPEUTICS INC | SHARE | 2026-06-30 | 2026-08-14 00:00:00 | 1946150.00 USD | 1380248.000000 | Shares | add | [Original filing](https://www.sec.gov/Archives/edgar/data/949509/0000949509-26-000005-index.html) |

Public disclosures can be delayed, incomplete, or amended. Report period describes a position date; transaction date describes a reported transaction; filed describes submission. A recent filing or page update does not establish a current holding. A dash means unavailable or not comparable, not zero.

This public summary shows the default reporting scope. Enable JavaScript for interactive filters, charts, and additional rows.

[How to read the data](https://ownershiptrace.com/docs#reading-the-data) · [Disclaimer](https://ownershiptrace.com/disclaimer)